Investigation of Novel Small Molecular TRPM4 Inhibitors in Colorectal Cancer Cells

• Published in: Cancers Vol. 13; no. 21; p. 5400
• Main Authors: Stokłosa, Paulina, Borgström, Anna, Hauert, Barbara, Baur, Roland, Peinelt, Christine
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 28.10.2021; MDPI
• Subjects: Acids; Androgens; Cancer; Cardiovascular diseases; Cell cycle; Cell proliferation; Colorectal cancer; Colorectal carcinoma; Lymphatic system; Software; Transient receptor potential proteins; Viability; United States > US
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13215400

(1) Background: Transient receptor potential melastatin (TRPM4) ion channel aberrant expression or malfunction contributes to different types of cancer, including colorectal cancer (CRC). However, TRPM4 still needs to be validated as a potential target in anti-cancer therapy. Currently, the lack of potent and selective TRPM4 inhibitors limits further studies on TRPM4 in cancer disease models. In this study, we validated novel TRPM4 inhibitors, CBA, NBA, and LBA, in CRC cells. (2) Methods: The potency to inhibit TRPM4 conductivity in CRC cells was assessed with the whole-cell patch clamp technique. Furthermore, the impact of TRPM4 inhibitors on cellular functions, such as viability, proliferation, and cell cycle, were assessed in cellular assays. (3) Results: We show that in CRC cells, novel TRPM4 inhibitors irreversibly block TRPM4 currents in a low micromolar range. NBA decreases proliferation and alters the cell cycle in HCT116 cells. Furthermore, NBA reduces the viability of the Colo205 cell line, which highly expresses TRPM4. (4) Conclusions: NBA is a promising new TRPM4 inhibitor candidate, which could be used to study the role of TRPM4 in cancer disease models and other diseases.